Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RNASE1 | P07998 | 1/20 | 0.62 |
| ▸ | TK1 | P04183 | 2/20 | 0.49 |
| ▸ | TYMS | P04818 | 1/20 | 0.48 |
| ▸ | TK2 | O00142 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | TSHR | P16473 | 2/20 | 0.48 |
| ▸ | ALB | P02768 | 1/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | BLM | P54132 | 1/20 | 0.48 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6046999 | 1.00 | RNASE1 (0.62) | RNASE1TK1TYMSTK2LMNA | |
| SCHEMBL14378872 | 0.93 | RNASE1 (0.53) | RNASE1TK1TYMSTK2 | |
| SCHEMBL13681649 | 0.88 | RNASE1 (0.66) | RNASE1TK1TK2ALBPKM | |
| SCHEMBL14094316 | 0.88 | RNASE1 (0.66) | RNASE1TK1TK2ALBPKM | |
| SCHEMBL31289411 | 0.87 | RNASE1 (0.50) | RNASE1TK1TYMS | |
| SCHEMBL8424441 | 0.83 | RNASE1 (0.53) | RNASE1TK1TYMSLMNATSHR | |
| SCHEMBL6046985 | 0.83 | RNASE1 (0.49) | RNASE1TK1TYMSTK2 | |
| SCHEMBL6046988 | 0.83 | RNASE1 (0.49) | RNASE1TK1TYMSTK2 | |
| SCHEMBL6047004 | 0.83 | TYMS (0.58) | TYMS | |
| SCHEMBL6047006 | 0.83 | TYMS (0.58) | TYMS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060154256-A1 | Method for covalently attaching nucleosides and/or nucleotides on surfaces and method for determining coupling yields in the synthesis of nucleotides | CHEMOGENIX GMBH (DE) | 2006-07-13 | — | — | US | disclosed |
| US-20040203036-A1 | Multimer polynucleotide synthesis | CHEMOGENIX GMBH (DE) | 2004-10-14 | — | — | US | disclosed |
| EP-1438322-A2 | METHOD FOR COVALENTLY ATTACHING NUCLEOSIDES AND/OR NUCLEOTIDES ON SURFACES AND METHOD FOR DETERMINING COUPLING YIELDS IN THE SYNTHESIS OF NUCLEOTIDES | Chemogenix GmbH (DE) | 2004-07-21 | — | — | EP | disclosed |
| EP-1409505-A1 | MULTIMER POLYNUCLEOTIDE SYNTHESIS | Chemogenix GmbH (DE) | 2004-04-21 | — | — | EP | disclosed |
| WO-2003035664-A2 | METHOD FOR COVALENTLY ATTACHING NUCLEOSIDES AND/OR NUCLEOTIDES ON SURFACES AND METHOD FOR DETERMINING COUPLING YIELDS IN THE SYNTHESIS OF NUCLEOTIDES | CHEMOGENIX GMBH (DE) | 2003-05-01 | — | — | WO | disclosed |
| WO-2003006476-A1 | MULTIMER POLYNUCLEOTIDE SYNTHESIS | CHEMOGENIX GMBH (DE) | 2003-01-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040203036-A1 | Multimer polynucleotide synthesis | NT5C3B, PCNA, POLL | RNASE1 205/4885TK1 176/4885TYMS 329/4885 |
| US-20060154256-A1 | Method for covalently attaching nucleosides and/or nucleotides on surfaces and method for determining coupling yields in the synthesis of nucleotides | NUDT1, PNP, NME2 | RNASE1 1368/4885TK1 71/4885TYMS 80/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.